Dilema Penggunaan Aspirin dan Proton Pump Inhibitor (PPI) Pada Pasien Gastroesophageal Reflux Disease Dengan Coronary Artery Disease (CAD)

Rizkia Hani Prahastutik, Muhammad Perdana Airlangga, Yudith Annisa Ayu Rezkitha, Detti Nur Irawati

Abstract


Latar belakang: Gastroesofageal Reflux Disease (GERD) ini sering terjadi pada penderita Coronary Artery Disease (CAD) dengan keluhan nyeri dada. Oleh karena itu obat antiplatelet digabungkan dengan Proton Pump Inhibitor (PPI) untuk pencegahan dari efek samping aspirin dan pengobatan GERD itu sendiri. Karena efek samping pendarahan gastrointestinal yang disebabkan oleh aspirin, Proton Pump Inhibitors (PPI) juga bisa berpengaruh mengurangi ketersediaan hayati aspirin, sehingga mengurangi kerja aspirin. Tujuan : untuk menganalisis munculnya dilema pengobatan pada pasien Gastroesophageal Reflux Disease (GERD) dengan Coronary Artery Disease (CAD). Metode: Artikel-artikel ilmiah terpublikasi tentang Gastroesophageal Refluks Disease (GERD) dengan Coronary Artery Disease (CAD) dicari menggunakan kata kunci Gastroesophageal Reflux Disease, Coronary Artery Disease, Antiplatelet, Proton Pump Inhibitors. dengan mendapatkan jumlah artikel sebanyak 1144877 dan telah melalui skrining sesuai dengan kriteria inlusi menjadi 7 jurnal Hasil : Pada pasien kunci Gastroesophageal Reflux Disease (GERD) dengan Coronary Artery Disease (CAD) Proton Pump Inhibitors (PPIs) sering dikombinasikan dengan antiplatelet yang telah terbukti secara efektif mengurangi resiko komplikasi pada gastrointestinal pada pasien. Namun, pada beberapa penelitian pemberian PPI akan mengurangi efek kemanjuran dari antiplatelet aspirin Kesimpulan: Penggunaan PPI pada GERD dianjurkan untuk digunakan dalam jangka pendek,karena penggunaan jangka panjang pada PPI meningkatkan resiko infark miokard, gagal ginjal, dan demensia. Pertimbangan pada resiko dan manfaat dengan mengkaji faktor resiko dari ganstrointestinal perlu diperhatikan

Kata kunci : Antiplatelet, Coronary Artery Disease, Gastroesophageal Proton Pump Inhibitors Reflux Disease,


Full Text:

PDF

References


Kemenkes RI. Infodatin Jantung. Jakarta. Kementrian Kesehatan Republik Indonesia.2014

Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7): 1–157. doi:10.1016/j.jacc.2007.02.013

Antman EM, Anbe DT, Armstrong PW Bates ER, Green LA, Hand M, et al. ACC/ AHA guidelines for the management of patients with STelevation myocardial infarctionexecutive summary: a report of the american college of cardiology/ american heart association task force on practice guidelines. Circulation. 2004;110(5):588–636. doi: 10.1161/01. CIR.0000134791.68010.FA

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324(7329):71– 86.

Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability: review of the published literature. Tex Heart I J. 2008;35(3):313– 20.

Sweetman S. Martindale The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009.

Lacy C, Amstrong L, Goldman M, Lance L. Drug Information Handbook. 17th ed. Washington: Lexi-Comp; 2009

BNF. British National Formulary. 73rd ed. London: BMJ Publishing Group; 2017.

Bjarnason I, Scarpignato C, Holmgren E, Olszewski M, Rainsford KD, Lanas A. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti- Inflammatory Drugs. Gastroenterology. 2018;154(3):500–14

Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One 2015;10(6):e0124653.

Tran-Duy A, Vanmolkot FH, Joore MA, Hoes AW, Stehouwer CDA. Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis. Int J Clin Pract 2015;69(10):1088–111.

Points K. Proton Pump Inhibitors ( PPIs ) and antiplatelet therapy Advisory guidance on when to initiate a PPI for gastro-protection Risk factors present No risk factors present High risk : Low risk : 2021;(March 2019):2019–21.

Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105(4):1650–5. doi: 10.1161/01.CIR.0000013777.21160.0 7

Sung JJY, Lau JYW, Ching JYL, Lee YT, Chiu PWY, Leung VKS, et al. Article Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding. Ann InternalMedicine. 2010;152(1):1–10.

WONG W, FASS R. Extraesophageal and atypical manifestations of GERD. J Gastroenterol Hepatol. 2004;19:S33– 43.

Indonesian Society of Gastroenterology (ISG). National consensus on the management of constipation in indonesia 2010. Acta Med Indones. 2011;43(4):267–74.

Lenfant C. Chest pain of cardiac and noncardiac origin. Metabolism. 2010;59(SUPPL. 1):S41–6. 18. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28.

Javed F, Ramee S. The Unknown Association of PPIs With Chest Pain in Patients With Known, Treated Coronary Artery Disease—A Diagnostic Dilemma. Curr Probl Cardiol [Internet]. 2016;41(7):235–44. Available from: http://www.sciencedirect.com/science/ article/pii/S0146280616300056

Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol. 2014;10(2):175– 89.

Gesheff MG, Franzese CJ, Bliden KP, Contino CJ, Rafeedheen R, Tantry US, et al. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Expert Rev Clin Pharmacol. 2014;7(5):645–53.

Lázaro AMP, Cristóbal C, FrancoPeláez JA, Tarín N, Aceña Á, Carda R, et al. Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease. PLoS One. 2017;12(1):1–13.

Peura DA, Mel Wilcox C. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and barrett’s esophagus. Postgrad Med. 2014;126(1):87–96.

Depta JP, Bhatt DL. Antiplatelet therapy and proton pump inhibition: Cause for concern? Curr Opin Cardiol. 2012;27(6):642–50.

Würtz M, Grove EL. Combining aspirin and proton pump inhibitors: For whom the warning bell tolls?Expert Opin Drug Metab Toxicol. 2012;8(9):1051–5.

Irawati S. Penatalaksanaan Gastroesophageal Reflux Disease (GERD). Bul Rasional. 2013;11(1):6– 8.

Saputera MD, Budianto W. Diagnosis dan tatalaksana gastroesophageal reflux disease (GERD) di pusat pelayanan kesehatan primer. J Contin Med Educ. 2017;44(5):329–32.

Ariel H, Cooke JP. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214–9.

Arbel Y, Birati EY, Finkelstein A, Halkin A, Kletzel H, Abramowitz Y, et al. Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: A prospective, randomized, crossover study. Clin Cardiol. 2013;36(6):342–6.

Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, et al. Effects of ppis and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19(6):559–69.




DOI: https://doi.org/10.18860/jim.v5i1.11572

Refbacks

  • There are currently no refbacks.


 

Editorial Office:

Faculty of Medical and Health Sciences,
Universitas Islam Negeri Maulana Malik Ibrahim
Gedung Ibnu Thufail Lt.1, Jln. Locari, Desa Tlekung, Kota Batu
Phone (+62) 85746163772, (+62) 8563588384, Faximile (+62) 341 558933
e-mail: medicaljournal@uin-malang.ac.id

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.